Ascentage Pharma Group International’s (AAPG) Buy Rating Reiterated at BTIG Research

BTIG Research reaffirmed their buy rating on shares of Ascentage Pharma Group International (NASDAQ:AAPG) in a research report released on Friday,Benzinga reports. They currently have a $48.00 price target on the stock.

Several other equities analysts have also recently issued reports on the stock. B. Riley Financial began coverage on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. They set a “buy” rating and a $45.00 target price on the stock. Raymond James Financial reiterated a “buy” rating on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Ascentage Pharma Group International in a report on Friday, April 24th. They set a “buy” rating and a $40.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $46.43.

Ascentage Pharma Group International Price Performance

Shares of AAPG opened at $17.00 on Friday. The business’s fifty day simple moving average is $18.20 and its two-hundred day simple moving average is $21.18. The company has a current ratio of 1.22, a quick ratio of 1.18 and a debt-to-equity ratio of 1.09. Ascentage Pharma Group International has a 12 month low of $16.36 and a 12 month high of $48.45.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its earnings results on Wednesday, August 19th. The company reported ($0.65) EPS for the quarter. The business had revenue of $22.24 million during the quarter. On average, equities analysts expect that Ascentage Pharma Group International will post -1.78 earnings per share for the current year.

Institutional Trading of Ascentage Pharma Group International

A number of hedge funds have recently bought and sold shares of AAPG. UBS Group AG lifted its holdings in Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after acquiring an additional 10,988 shares during the period. Hsbc Holdings PLC bought a new stake in shares of Ascentage Pharma Group International during the 2nd quarter valued at about $391,000. Finally, Citadel Advisors LLC bought a new stake in shares of Ascentage Pharma Group International during the 3rd quarter valued at about $383,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.